Skip to main content
Premium Trial:

Request an Annual Quote

Migrations: Dec 19, 2008

Platypus Technologies this week announced that Richard Schifreen has joined the company as president and chief executive officer. He was previously vice president of research products at Mirus Bio.
Prior to joining Mirus Bio in 2005, Schifreen was the director of technology and business development at Promega.    
The company also announced that Jeffrey Williams, the former president and chief executive officer of Platypus, has left the company to pursue opportunities in molecular biology.    

Cellular Dynamics International announced this week that Chris Kendrick-Parker has been appointed chief commercial officer, Emile Nuwaysir has been appointed chief operating officer, and David Snyder has been appointed chief financial officer.
Prior to CDI, Kendrick-Parker served as vice president of the global pharmaceutical business unit at Affymetrix. Kendrick-Parker was previously a member of the drug discovery services team at Amersham Pharmacia.
Nuwaysir was senior vice president of program management and business development and chief technology officer at Roche NimbleGen, prior to CDI. Nuwaysir previously held various scientific and managerial positions at NimbleGen.
Snyder most recently was site vice president and chief financial officer of Roche NimbleGen.  

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.